A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. (21st February 2017)

• Record Type: Journal Article
• Authors: Sawas, Ahmed; Farber, Charles M.; Schreeder, Marshall T.; Khalil, Mazen Y.; Mahadevan, Daruka; Deng, Changchun; Amengual, Jennifer E.; Nikolinakos, Petros G.; Kolesar, Jill M.; Kuhn, John G.; Sportelli, Peter; Miskin, Hari P.; O'Connor, Owen A.
• Is Part Of: British journal of haematology. Volume 177:Number 2(2017)
• Page Start: 243
• Page End: 253
• Publication Date: 2017-02-21
• Subjects: anti‐CD20 monoclonal antibody -- B‐cell lymphoma -- LFB‐R603 -- TG‐1101 -- ublituximab; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.14534
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti‐tumour activity of ublituximab, a unique type I, chimeric, glycoengineered anti‐CD20 monoclonal antibody, in rituximab‐relapsed or ‐refractory patients with B‐cell non‐Hodgkin lymphoma (B‐NHL) or chronic lymphocytic leukaemia (CLL). Induction therapy (doses of 450–1200 mg) consisted of 4 weekly infusions in cycle 1 for NHL and 3 weekly infusions in cycles 1 and 2 for CLL. Patients received ublituximab maintenance monthly during cycles 3–5, then once every 3 months for up to 2 years. Enrolled patients with B‐NHL ( n = 27) and CLL ( n = 8) had a median of 3 prior therapies. No dose‐limiting toxicities or unexpected adverse events (AEs) occurred. The most common AEs were infusion‐related reactions (40%; grade 3/4, 0%); fatigue (37%; grade 3/4, 3%); pyrexia (29%; grade 3/4, 0%); and diarrhoea (26%; grade 3/4, 0%). Common haematological AEs were neutropenia (14%; grade 3/4, 14%) and anaemia (11%; grade 3/4, 6%). The overall response rate for evaluable patients ( n = 31) was 45% (13% complete responses, 32% partial responses). Median duration of response and progression‐free survival were 9·2 months and 7·7 months, respectively. Ublituximab was well‐tolerated and efficacious in a heterogeneous and highly rituximab‐pre‐treated patient population.